Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.83 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.82 |
| ▸ | HTT | P42858 | 2/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.49 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.49 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL426740 | 0.86 | L3MBTL1 (0.69) | KDM4EL3MBTL1HTTSMN1; SMN2CYP1A2 | |
| SCHEMBL427937 | 0.85 | KDM4E (0.62) | KDM4EL3MBTL1HTTSMN1; SMN2CYP1A2 | |
| SCHEMBL448001 | 0.85 | CYP1A2 (0.64) | KDM4EL3MBTL1HTTSMN1; SMN2CYP1A2 | |
| SCHEMBL30339057 | 0.84 | KDM4E (0.65) | KDM4EL3MBTL1HTTSMN1; SMN2CYP1A2 | |
| SCHEMBL16643959 | 0.81 | CYP2D6 (0.97) | KDM4EL3MBTL1HTTCYP1A2CYP2D6 | |
| SCHEMBL10183563 | 0.81 | CYP1A2 (0.63) | KDM4EL3MBTL1HTTSMN1; SMN2CYP1A2 | |
| SCHEMBL447689 | 0.81 | CYP2D6 (0.59) | KDM4EL3MBTL1HTTSMN1; SMN2CYP1A2 | |
| SCHEMBL9912418 | 0.80 | SMN1; SMN2 (0.74) | KDM4EL3MBTL1HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL12409045 | 0.80 | SMN1; SMN2 (0.74) | KDM4EL3MBTL1HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL12218602 | 0.80 | CYP2D6 (1.00) | KDM4EL3MBTL1HTTCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-8058445-B2 | Substituted pyridinecarboxamides for the treatment of cancer | AMGEN INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7514564-B2 | Substituted amine derivatives and methods of use | AMGEN INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514564-B2 | Substituted amine derivatives and methods of use | AMGEN INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1562933-B1 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATED DISORDERS | AMGEN INC (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1798230-A1 | Substituted alkylamine derivatives and methods of use | Amgen Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | KDM4E 1013/4885L3MBTL1 1828/4885HTT 1813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.